Clearmind announces patent application for metabolic syndrome treatment

VANCOUVER - Clearmind Medicine Inc. (Nasdaq:CMND), a micro-cap biotech company with a current market capitalization of $4.93 million, announced Thursday the publication of an international patent application for a combination therapy targeting metabolic syndrome and obesity. According to InvestingPro data, the company maintains a healthy balance sheet with more cash than debt, despite being in pre-revenue stage.

The patent application, published under the European Patent Office as part of the Patent Cooperation Treaty, covers a therapy combining Clearmind’s 5-methoxy-2-aminoindane (MEAI) with SciSparc Ltd.’s (Nasdaq:SPRC) Palmitoylethanolamide (PEA).

Metabolic syndrome, which affects approximately one-third of U.S. adults, is characterized by conditions including high blood pressure, elevated blood sugar, excess abdominal fat, and high cholesterol levels. These conditions increase the risk of heart disease, stroke, obesity, and type 2 diabetes.

The patent publication represents a milestone in the ongoing collaboration between Clearmind and SciSparc, which has resulted in 13 patent families filed across multiple jurisdictions including the United States, Europe, and China.

"We continue our strategy to develop breakthrough therapies to treat complex health conditions," said Dr. Adi Zuloff-Shani, CEO of Clearmind, according to the company’s press release. The company’s stock has faced challenges, trading 56% below its 52-week high of $2.18, with a year-to-date decline of over 30%.

The collaboration focuses on developing therapies that combine neuroplastogen molecules with N-acylethanolamines, including PEA, to address various conditions including mental health disorders, addictions, and metabolic conditions.

Clearmind Medicine is a clinical-stage psychedelic pharmaceutical biotech company with an intellectual portfolio consisting of nineteen patent families including 31 granted patents.

The information in this article is based on a press release statement from Clearmind Medicine Inc.

In other recent news, Clearmind Medicine Inc. has made significant advancements in its Phase I/IIa clinical trial for CMND-100, aimed at treating Alcohol Use Disorder (AUD). The company announced the completion of site initiation at Tel Aviv Sourasky Medical Center, allowing the trial to proceed at this new location. This follows the expansion of the trial to include a new clinical site at Johns Hopkins University School of Medicine, where the first participant has already been enrolled. Additionally, Clearmind received Institutional Review Board approval from Tel Aviv Sourasky Medical Center, enabling patient enrollment at this site. The trial is also being conducted at Yale School of Medicine and Hadassah-University Medical Center in Jerusalem. Clearmind has successfully dosed the first participant with its MEAI-based oral drug candidate, CMND-100, across these multiple clinical sites. The study focuses on evaluating the safety, tolerability, and pharmacokinetic profile of CMND-100, as well as exploring early efficacy signals such as reduced alcohol cravings and consumption.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.